HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to ...
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now ...
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating today. Joseph Pantginis has ...
Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed yesterday at $55.28.
Purpose-driven marketing elevates brand-consumer relationships beyond transactional interactions. By linking brand values ...
The biological needs of plants and animals affect their cells' protein content, but the story goes deeper than that.
Live imaging at single-vesicle resolution reveals rabphilin-3A as the first identified negative regulator of neuropeptide release in mammalian neurons.
ORDINARY aqueous or potassium chloride extracts of muscle exhibit but a slight capacity to mineralize adenosinetriphosphate. Even this slight liberation of phosphate is mainly due, not to direct ...